BMY · Bristol-Myers Squibb Company

Big pharma: Eliquis, Opdivo, and a new-launch pipeline

Risiko 5/10 · MODERATE RISK · patent-cliff pharma · $66.82 ▼ 1.87%🤖Von KI geschrieben

Stand der Zahlen: 07.09.2026 · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

• Price $66.82
• Market cap $136.5B
• P/E (ttm) 14.72
• Div yield 3.77%
• 52-wk range $42.52 – $68.64
• Index rank #102 / —

Wichtigste Risiken

• Eliquis and Opdivo exclusivity losses blow a revenue hole (Shareholders) — HIGH
• Heavy acquisition debt limits pipeline-buying firepower (Bondholders) — HIGH
• New launches (Cobenfy, CELMoD) ramp too slowly to fill the gap (Shareholders) — MED
• Revived multi-billion-dollar Celgene-era lawsuit (Shareholders) — MED

Fazit

The single-digit forward multiple only works if the launch portfolio actually replaces the cliff — a value bet on execution, not a sleep-well dividend stock.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.